Form 4: OptiNose Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., reports acquisition and disposition of company stock related to vesting of restricted stock units and tax obligations.
Summary
- On March 15, 2024, Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., acquired 3,816 shares of common stock due to the vesting of performance-based restricted stock units (Performance RSUs).
- These Performance RSUs were granted on March 6, 2020, with 50% vesting on June 15, 2022, upon achievement of certain milestones, and the balance vesting in eight equal quarterly installments.
- On March 18, 2024, Marino disposed of 15,059 shares of common stock at a price of $1.88 per share.
- This disposition was to cover tax withholding obligations related to the vesting of restricted share units.
- Following these transactions, Marino beneficially owns 602,268 shares of OptiNose, Inc. common stock.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and tax obligations. It doesn't indicate any significant positive or negative developments for the company.
Positives
- The vesting of performance-based restricted stock units indicates that the company has achieved certain milestones in its development programs.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates activity related to equity compensation and tax obligations, which is common for publicly traded companies.
Comparison to Industry Standards
- Equity compensation is a standard practice in the pharmaceutical industry to incentivize and retain key personnel.
- The vesting schedule of the performance-based restricted stock units, with milestones and quarterly installments, is a typical structure for aligning employee incentives with company performance.
- The 'sell to cover' transaction for tax withholding is a common mechanism used by companies to manage the tax implications of equity awards for their employees.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they relate to executive compensation and tax obligations.
- Employees who hold similar equity awards may be interested in the details of the vesting schedule and tax implications.
Key Dates
| Date | Description |
|---|---|
| March 6, 2020 | Date of grant for performance-based restricted stock units (Performance RSUs). |
| June 15, 2022 | Fifty percent (50%) of the Performance RSUs vested upon achievement of certain milestones. |
| March 15, 2024 | Acquisition of 3,816 shares of common stock due to vesting of Performance RSUs. |
| March 18, 2024 | Disposition of 15,059 shares of common stock at $1.88 per share to cover tax withholding obligations. |
| March 19, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.